Maze Therapeutics冲刺纳斯达克：拟募资1.3亿美元路演PPT曝光

雷递网01-28

雷递网雷建平 1月28日临床阶段的生物制药公司Maze Therapeutics(股票代码为：“MAZE”)日前更新招股书，准备2025年1月31日在美国纳斯达克上市。Maze Therapeutics发行区间为15美元到17美元，发行780万股，最高募资1.33亿美元。9个月许可收入1.68亿美元Maze Therapeutics是一家临床阶段的生物制药公司，利用人类遗传学的力量为患有常见疾病...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2506566034?lang=zh_CN&edition=full","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250128/6387367190475143803689168.jpeg","is_english":false,"pubTime":"2025-01-28 14:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2506566034","market":"us","top_or_hot":-1,"title":"Maze Therapeutics冲刺纳斯达克：拟募资1.3亿美元 路演PPT曝光","media":"雷递网","content":"<div>\n<p>雷递网 雷建平 1月28日临床阶段的生物制药公司Maze Therapeutics(股票代码为：“MAZE”)日前更新招股书，准备2025年1月31日在美国纳斯达克上市。Maze Therapeutics发行区间为15美元到17美元，发行780万股，最高募资1.33亿美元。9个月许可收入1.68亿美元Maze Therapeutics是一家临床阶段的生物制药公司，利用人类遗传学的力量为患有常见疾病...</p>\n\n<a href=\"https://www.leinews.com/n28902/detail.html\">网页链接</a>\n\n</div>\n","source":"leinews_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Maze Therapeutics冲刺纳斯达克：拟募资1.3亿美元 路演PPT曝光</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaze Therapeutics冲刺纳斯达克：拟募资1.3亿美元 路演PPT曝光\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-28 14:38 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.leinews.com/n28902/detail.html><strong>雷递网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>雷递网 雷建平 1月28日临床阶段的生物制药公司Maze Therapeutics(股票代码为：“MAZE”)日前更新招股书，准备2025年1月31日在美国纳斯达克上市。Maze Therapeutics发行区间为15美元到17美元，发行780万股，最高募资1.33亿美元。9个月许可收入1.68亿美元Maze Therapeutics是一家临床阶段的生物制药公司，利用人类遗传学的力量为患有常见疾病...</p>\n\n<a href=\"https://www.leinews.com/n28902/detail.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_MNQ","symbol_name":"微型NQ100指数","start_time":0,"source_url":"https://www.leinews.com/n28902/detail.html","article_id":"2506566034","we_media_id":null,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250128/6387367190475143803689168.jpeg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2506566034","pubTimestamp":1738046309,"columns":[],"sourceInfo":{"source_id":"leinews_highlight","name":"雷帝触网"},"weMediaInfo":null,"summary":"临床阶段的生物制药公司Maze Therapeutics(股票代码为：“MAZE”)日前更新招股书，准备2025年1月31日在美国纳斯达克上市。Maze Therapeutics发行区间为15美元到17美元，发行780万股，最高募资1.33亿美元。","collect":0,"end_time":0,"defaultTopTitle":"leinews.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{".IXIC":"NASDAQ Composite","NDX":"纳斯达克100指数","QID":"两倍做空纳斯达克指数ETF-ProShares","USAW.SI":"AMZN 3xLongSG261006","BK4007":"制药","NVIW.SI":"NVDA 3xLongSG261006","LENZ":"Therapeutics","TQQQ":"纳指三倍做多ETF","03086":"华夏纳指","PPT":"普特南优先收入信托","PSQ":"做空纳斯达克100指数ETF-ProShares","SQQQ":"纳指三倍做空ETF","BK1147":"投资银行业与经纪业","BK4139":"生物科技","MAZE":"Maze Therapeutics","QLD":"2倍做多纳斯达克100指数ETF-ProShares","USJW.SI":"ALPHAB 3xLongSG261006","ARTL":"Artelo Biosciences, Inc.","TSYW.SI":"TESLA 3xLongSG261006"},"translate_title":"Maze Therapeutics sprints to Nasdaq: plans to raise US $130 million roadshow PPT exposed","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"USAW.SI":0.6,"QID":0.6,"NDX":1,".IXIC":1,"TQQQ":0.6,"MAZE":1,"PSQ":0.6,"LENZ":1,"NVIW.SI":0.6,"TSYW.SI":0.6,"QLD":0.6,"03086":1,"USJW.SI":0.6,"SQQQ":0.6,"ARTL":1,"PPT":1,"NQmain":0.6,"MNQmain":0.6},"content_text":"雷递网 雷建平 1月28日临床阶段的生物制药公司Maze Therapeutics(股票代码为：“MAZE”)日前更新招股书，准备2025年1月31日在美国纳斯达克上市。Maze Therapeutics发行区间为15美元到17美元，发行780万股，最高募资1.33亿美元。9个月许可收入1.68亿美元Maze Therapeutics是一家临床阶段的生物制药公司，利用人类遗传学的力量为患有常见疾病的患者开发新型小分子精准药物，重点关注肾脏、心血管和相关代谢，包括肥胖症。Maze Therapeutics正利用其Compass 平台推进管道，该平台提供对疾病遗传变异洞察，并将其与特定患者群体中驱动疾病生物途径联系起来。Maze Therapeutics的管道由两个全资拥有的领先项目 MZE829 和 MZE782 领导，每个项目都代表了一种基于精准医学的慢性肾病新方法。招股书显示，Maze Therapeutics在2022年、2023年无营收，在2024年前9个月获得的许可收入（License revenue）为1.68亿美元。Maze Therapeutics在2022年、2023年运营亏损分别为1.11亿美元、9855万美元；净亏损分别为1.15亿美元、1亿美元。Maze Therapeutics在2024年前9个月运营利润为8731万美元，上年同期的运营亏损为7550万美元；净利为8181万美元，上年同期的净亏损为7384万美元。刚完成1.15亿美元融资Maze Therapeutics在2024年12月完成1.15亿美元的D系列轮融资，其中包括转换先前由现有投资者购买的已发行可转换票据。D 轮融资由投资者 Frazier Life Sciences 和 Deep Track Capital 共同领投。Janus Henderson Investors 和 Logos Capital也参与其中，现有投资者包括 Third Rock Ventures、ARCH Venture Partners、Matrix Capital Management Partners、GV、General Catalyst、Andreessen Horowitz (a16z)、Foresite Capital、Woodline Partners LP、Casdin Capital等。IPO前，ARCH Venture Partners持股为11.8%，GV持股为6.9%，Third Rock Ventures持股为20.1%，Matrix Capital Management Master Fund持股为7.1%，Foresite Capital Fund IV持股为6.7%。IPO后，ARCH Venture Partners持股为9.6%，GV持股为5.6%，Third Rock Ventures持股为16.4%，Matrix Capital Management Master Fund持股为5.8%，Foresite Capital Fund IV持股为5.4%。以下是Maze Therapeutics路演PPT：———————————————雷递由媒体人雷建平创办，若转载请写明来源。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2506566034","isCrawlerRequest":true}

Maze Therapeutics冲刺纳斯达克：拟募资1.3亿美元 路演PPT曝光

精彩评论

Maze Therapeutics冲刺纳斯达克：拟募资1.3亿美元路演PPT曝光